U.S. Markets closed
  • S&P 500

    3,923.68
    -165.17 (-4.04%)
     
  • Dow 30

    31,490.07
    -1,164.52 (-3.57%)
     
  • Nasdaq

    11,418.15
    -566.37 (-4.73%)
     
  • Russell 2000

    1,774.85
    -65.45 (-3.56%)
     
  • Crude Oil

    108.88
    -3.52 (-3.13%)
     
  • Gold

    1,814.70
    -4.20 (-0.23%)
     
  • Silver

    21.50
    -0.24 (-1.09%)
     
  • EUR/USD

    1.0468
    -0.0087 (-0.8270%)
     
  • 10-Yr Bond

    2.8860
    -0.0820 (-2.76%)
     
  • Vix

    30.96
    +4.86 (+18.62%)
     
  • GBP/USD

    1.2341
    -0.0152 (-1.2131%)
     
  • USD/JPY

    128.2100
    -1.1480 (-0.8875%)
     
  • BTC-USD

    29,164.12
    -993.49 (-3.29%)
     
  • CMC Crypto 200

    650.14
    -20.54 (-3.06%)
     
  • FTSE 100

    7,438.09
    -80.26 (-1.07%)
     
  • Nikkei 225

    26,911.20
    +251.45 (+0.94%)
     

My Top Growth Stock to Buy on Sale for 2022

·5 min read
My Top Growth Stock to Buy on Sale for 2022
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Doximity (NYSE: DOCS) is one of those investments that has fallen sharply from its all-time highs. Despite this recent volatility, Doximity is the leading app for healthcare professionals in the U.S. with over 1.8 million medical workers on its platform. With such a large discount on Doximity's stock now, investors might want to consider adding this market leader to their portfolios.